Geron Announces Two Poster Presentations at Upcoming American Society of Hematology Annual Meeting
November 06 2019 - 9:18AM
Geron Corporation (Nasdaq: GERN) today announced that two abstracts
related to imetelstat, the Company’s first-in-class telomerase
inhibitor, have been accepted for presentation at the 61st American
Society of Hematology (ASH) Annual Meeting and Exposition to be
held in Orlando, Florida from December 7-10, 2019. The abstracts
were published today on the ASH website at www.hematology.org.
Poster Presentations
Title: IMerge: A Study to Evaluate Imetelstat (GRN163L)
in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1
Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to
Erythropoiesis-Stimulating Agent (ESA) Treatment (Abstract
#4248)
Session Name: 637. Myelodysplastic Syndromes—Clinical Studies:
Poster III Session Date: Monday, December 9, 2019 Session Time:
6:00 p.m. ET - 8:00 p.m. ET As of this year, ASH has created a new
category for abstract submissions called Trials in Progress.
Abstracts for this category describe innovative clinical trials
that have not reached their primary endpoint to provide
opportunities for early engagement and collaboration amongst
investigators, translational research, clinical and industry
investigators, statisticians and regulators. The Phase 3 IMerge
clinical trial will be presented as a poster in this new category,
and the details of the trial design are described in the
abstract.
Title: Combination Treatment with Imetelstat, a
Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis
Hematopoietic Stem Cells and Progenitor Cells (Abstract
#2963)
Session Name: 635. Myeloproliferative Syndromes: Basic Science:
Poster IISession Date: Sunday, December 8, 2019 Session Time: 6:00
p.m. ET - 8:00 p.m. ET The abstract reports results from early,
nonclinical experiments on the potential effect of combining
imetelstat and ruxolitinib on malignant myelofibrosis (MF) cells.
The experiments explored the hypothesis that the combination of
imetelstat and ruxolitinib might create a treatment regimen for MF
that could be more efficacious than using either drug alone in
reducing myelofibrosis hematopoietic stem cells and hematopoietic
progenitor cells. In the experiments, the regimen of sequential
treatment of ruxolitinib followed by imetelstat resulted in greater
reductions in the MF hematopoietic stem and progenitor cells,
compared to when either drug was used alone or simultaneously. In
addition, the sequential treatment regimen did not affect normal
hematopoietic stem and progenitor cells. As stated in the abstract,
these findings suggest that an additive inhibitory activity against
malignant myelofibrosis hematopoietic stem and progenitor cells can
be achieved using a sequential treatment regimen of ruxolitinib
followed by imetelstat.
About Imetelstat
Imetelstat is a novel, first-in-class telomerase inhibitor
exclusively owned by Geron and being developed in hematologic
myeloid malignancies. Early clinical data suggest imetelstat may
have disease-modifying activity through the suppression of
malignant progenitor cell clone proliferation, which allows
potential recovery of normal hematopoiesis. Ongoing clinical
studies of imetelstat consist of IMerge, a Phase 2/3 trial in lower
risk myelodysplastic syndromes (MDS), and IMbark, a Phase 2 trial
in Intermediate-2 or High-risk myelofibrosis (MF). Imetelstat has
been granted Fast Track designation by the United States Food and
Drug Administration for both the treatment of patients with
non-del(5q) lower risk MDS who are refractory or resistant to an
erythropoiesis-stimulating agent and for patients with
Intermediate-2 or High-risk MF whose disease has relapsed after or
is refractory to janus kinase (JAK) inhibitor treatment.
About Geron
Geron is a clinical stage biopharmaceutical company focused on
the development and potential commercialization of a first-in-class
telomerase inhibitor, imetelstat, in hematologic myeloid
malignancies. For more information about Geron, visit
www.geron.com.
Use of Forward-Looking Statements
Except for the historical information contained herein, this
press release contains forward-looking statements made pursuant to
the “safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such statements,
include, without limitation, those regarding: (i) that imetelstat
may have disease-modifying activity; and (ii) other statements that
are not historical facts, constitute forward looking statements.
These statements involve risks and uncertainties that can cause
actual results to differ materially from those in such
forward-looking statements. These risks and uncertainties, include,
without limitation, risks and uncertainties related to: (i) whether
imetelstat actually demonstrates disease-modifying activity in
patients; and (ii) whether imetelstat has adequate patent
protection and freedom to operate. Additional information on the
above risks and uncertainties and additional risks, uncertainties
and factors that could cause actual results to differ materially
from those in the forward-looking statements are contained in
Geron’s periodic reports filed with the Securities and Exchange
Commission under the heading “Risk Factors,” including Geron’s
quarterly report on Form 10-Q for the quarter ended June 30, 2019.
Undue reliance should not be placed on forward-looking statements,
which speak only as of the date they are made, and the facts and
assumptions underlying the forward-looking statements may change.
Except as required by law, Geron disclaims any obligation to update
these forward-looking statements to reflect future information,
events or circumstances.
CONTACT:
Suzanne MessereInvestor and Media
Relationsinvestor@geron.commedia@geron.com
CG Capital877-889-1972
Geron (NASDAQ:GERN)
Historical Stock Chart
From Apr 2024 to May 2024
Geron (NASDAQ:GERN)
Historical Stock Chart
From May 2023 to May 2024